The FDA approved Revolution Medicines’ oral pan-RAS inhibitor daraxonrasib (Rasonque) for advanced pancreatic ductal adenocarcinoma, positioning it as a new treatment option based on survival gains in a practice-changing phase 3 program. The approval covers patients who have progressed on standard therapies. Revolution’s daraxonrasib is designed to target RAS-driven signaling, an approach that aims to address the limited durability seen with chemotherapy in metastatic pancreatic cancer. The pivotal trial readouts earlier this year showed materially longer overall survival versus standard chemotherapy in the studied population. Analysts and oncologists emphasized the speed and scope of the regulatory decision, which signals momentum for mechanism-driven therapies in a disease area that has struggled to deliver sustained benefit. Market impact is expected as the label expansion translates into earlier access for eligible patients and a platform for subsequent studies and combinations.